Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Classical hematology 1

Conditions

Multiple Myeloma 2121Neoplasms, Plasma Cell 505Lymphoma 354Lymphoma, Non-Hodgkin 334Hodgkin Disease 329Leukemia, Lymphocytic, Chronic, B-Cell 307Precursor Cell Lymphoblastic Leukemia-Lymphoma 299Leukemia 290Leukemia, Myeloid, Acute 270Myelodysplastic Syndromes 263Lymphoma, Mantle-Cell 228Lymphoma, Follicular 224Lymphoma, Large B-Cell, Diffuse 216Lymphoma, B-Cell, Marginal Zone 206Burkitt Lymphoma 201Recurrence 188Myeloproliferative Disorders 182Lymphoma, Large-Cell, Immunoblastic 182Immunoglobulin Light-chain Amyloidosis 162Primary Myelofibrosis 153Leukemia, Myeloid, Chronic-Phase 152Leukemia, Myeloid, Accelerated Phase 143Lymphoma, T-Cell, Cutaneous 140Leukemia, Myelomonocytic, Chronic 133Blast Crisis 131Mycosis Fungoides 126Sezary Syndrome 125Congenital Abnormalities 122Waldenstrom Macroglobulinemia 121Leukemia, Hairy Cell 110

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 1Immunoglobulins 1Hizentra 1Clavulanic Acid 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Agammaglobulinemia × Plasma cell × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

NCT05678621 2024-04-19

RATIONALISE

Monash University

Phase 2/3 Recruiting
300 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡